In our previous work,7 we identified IL34 as a potential biomarker of RCC progression, as its expression was gradually upregulated in serially implanted Renca cells in a cell passage-dependent manner (Figure S1A) and was concomitant with an increase in tumor aggressiveness. This evidence concerns the gene IL34 and neoplasm.